4 completed, 1 terminated, 1 unknown, 1 withdrawn. 2 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Weekly Paclitaxel: new trials by email Literature Review of Weekly Paclitaxel trials Research Report on Weekly Paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) NovoTTF-100L(O), Paclitaxel - Ovarian Cancer | Phase 3 | Completed | NovoCure Ltd. | 540 | 2019-03-22 | 2024-03-29 |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling Doxorubicin, Cyclophosphamide, Weekly Paclitaxel - HER2-negative Breast Cancer | Phase 2 | Unknown | NSABP Foundation Inc | 64 | 2018-05-14 | 2023-03-06 |
| Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer Weekly paclitaxel, Topotecan, Pegylated liposomal doxorubicin - Ovarian Cancer | Completed | Yonsei University | 50 | 2017-09-01 | 2019-01-11 | |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients Trabectedin, Pegylated Liposomal Doxorubicin, Topotecan - Ovarian Neoplasms | Phase 3 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 242 | 2016-04-11 | 2021-08-25 |
| Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) Pazopanib, Paclitaxel - Penile Squamous Cell Carcinoma Stage IV | Phase 2 | Terminated | Spanish Oncology Genito-Urinary Group | 4 | 2015-01-01 | 2016-10-14 |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer weekly paclitaxel, weekly cisplatin, oncothermia - Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Completed | Seoul National University Hospital | 12 | 2014-12-01 | 2024-07-12 |
| Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer Trastuzumab, Weekly Paclitaxel, Carboplatin - Breast Cancer, HER-2 Positive Breast Cancer | Not applicable | Withdrawn | Instituto do Cancer do Estado de São Paulo | 2014-04-01 | 2016-08-31 |
Ovarian Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Recurrence (1)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Instituto do Cancer do Estado de São Paulo (1) · NSABP Foundation Inc (1) · NovoCure Ltd. (1) · Seoul National University Hospital (1) · Spanish Oncology Genito-Urinary Group (1) · Yonsei University (1)
Italy (2) · South Korea (2) · Spain (2) · United States (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Israel (1) · Netherlands (1) · Poland (1) · Switzerland (1)
Debora de Gagliato, MD (1) · Domenica Lorusso, Prof. (1) · Ignace Vergote, MD (1) · Max Se Mano, MD phD (1) · Miguel A Climent, MD (1) · Norman Wolmark, MD (1)
PMID 10655437, PMID 11165136, PMID 11304695, PMID 11479630, PMID 16912194, PMID 21376569, PMID 21835933, PMID 23397080, PMID 23410977, PMID 30409490, PMID 34055086, PMID 38315944
2014 (1)